Overview Dividends

(ACB) Aurora Cannabis - Ratings and Ratios

Exchange: NASDAQ • Country: Canada • Currency: USD • Type: Common Stock • ISIN: CA05156X8843

Dried Cannabis, Cannabis Oil, Capsules, Edibles, Vaporizers, Concentrates

ACB EPS (Earnings per Share)

EPS Growth (3Y CAGR): -72.04%
EPS Trend (3Y Correlation): -7.2%

ACB Revenue

Revenue Growth (3Y CAGR): 17.58%
Revenue Trend (3Y Correlation): 86.2%

Risk via 10d forecast
Volatility	72.8%
Value at Risk 5%th	95.8%
Relative Tail Risk	-20.09%

Reward TTM
Sharpe Ratio	0.27
Alpha	-27.15

Character TTM
Hurst Exponent	0.430
Beta	1.445
Beta Downside	1.376

Drawdowns 3y
Max DD	79.36%
Mean DD	59.01%
Median DD	62.00%

Description: ACB Aurora Cannabis October 28, 2025

Aurora Cannabis Inc. (NASDAQ: ACB) produces, distributes, and sells a broad portfolio of pharmaceutical-grade and consumer cannabis products across Canada and select international markets. The firm operates two reporting segments-Canadian Cannabis, which focuses on dried flower, oils, concentrates and vaporizers, and Plant Propagation, which cultivates vegetables and ornamental plants for wholesale distribution.

As of Q2 2024, Aurora reported net revenue of $322 million, a 12 % YoY increase driven by higher wholesale prices and expanding medical-patient enrollment in Canada. The company’s cash-burn rate has narrowed to roughly $45 million per quarter, reflecting tighter cost controls and the closure of under-performing facilities. A key sector driver remains the Canadian federal framework that caps recreational sales growth at ~15 % annually, while U.S. federal legalization prospects continue to shape long-term upside for international brands such as Pedanios and Bidiol.

For a deeper dive into Aurora’s valuation metrics and how they compare to peer benchmarks, you may find ValueRay’s analytical tools useful for extending your research.

ACB Stock Overview

Market Cap in USD	257m
Sub-Industry	Pharmaceuticals
IPO / Inception	2014-07-11
Return 12m vs S&P 500	-13.4%
Analyst Rating	4.17 of 5

ACB Dividends

Currently no dividends paid

ACB Growth Ratios

CAGR 3y	-31.90%
CAGR/Max DD Calmar Ratio	-0.40
CAGR/Mean DD Pain Ratio	-0.54
Current Volume	1028.9k
Average Volume	1064.9k

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (-14.3m TTM) > 0 and > 6% of Revenue (6% = 21.8m TTM)

FCFTA -0.00 (>2.0%) and ΔFCFTA 8.13pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 101.2% (prev 104.1%; Δ -2.96pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.02 (>3.0%) and CFO 17.8m > Net Income -14.3m (YES >=105%, WARN >=100%)

Net Debt (-33.3m) to EBITDA (67.5m) ratio: -0.49 <= 3.0 (WARN <= 3.5)

Current Ratio 4.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (55.8m) change vs 12m ago -1.00% (target <= -2.0% for YES)

Gross Margin 60.97% (prev 54.96%; Δ 6.01pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 43.72% (prev 36.64%; Δ 7.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 6.13 (EBITDA TTM 67.5m / Interest Expense TTM 8.27m) >= 6 (WARN >= 3)

Altman Z'' -18.67

(A) 0.43 = (Total Current Assets 478.3m - Total Current Liabilities 110.9m) / Total Assets 852.7m

(B) -7.47 = Retained Earnings (Balance) -6.37b / Total Assets 852.7m

warn (B) unusual magnitude: -7.47 — check mapping/units

(D) 2.32 = Book Value of Equity 567.2m / Total Liabilities 244.1m

Total Rating: -18.67 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 59.81

1. Piotroski 4.50pt = -0.50

2. FCF Yield -0.31% = -0.15

3. FCF Margin -0.28% = -0.10

4. Debt/Equity 0.18 = 2.48

5. Debt/Ebitda -0.49 = 2.50

6. ROIC - WACC (= -0.08)% = -0.10

7. RoE -2.55% = -0.43

8. Rev. Trend 86.23% = 6.47

9. EPS Trend -7.20% = -0.36

What is the price of ACB shares?

As of November 15, 2025, the stock is trading at USD 4.31 with a total of 1,028,890 shares traded.
Over the past week, the price has changed by -5.27%, over one month by -21.49%, over three months by -20.04% and over the past year by -0.69%.

Is Aurora Cannabis a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Aurora Cannabis is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 59.81 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACB is around 2.97 USD . This means that ACB is currently overvalued and has a potential downside of -31.09%.

Is ACB a buy, sell or hold?

Aurora Cannabis has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy ACB.

Strong Buy: 3
Buy: 1
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ACB price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	6.2	44.3%
Analysts Target Price	6.2	44.3%
ValueRay Target Price	3.3	-22.5%

ACB Fundamental Data Overview November 11, 2025

Market Cap CAD = 360.9m (257.4m USD * 1.402 USD.CAD)
P/E Forward = 13.4048
P/S = 0.7012
P/B = 0.8061
Beta = 1.256
Revenue TTM = 363.2m CAD
EBIT TTM = 50.6m CAD
EBITDA TTM = 67.5m CAD
Long Term Debt = 40.2m CAD (from longTermDebt, last fiscal year)
Short Term Debt = 26.9m CAD (from shortTermDebt, last fiscal year)
Debt = 104.6m CAD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -33.3m CAD (from netDebt column, last fiscal year)
Enterprise Value = 327.0m CAD (360.9m + Debt 104.6m - CCE 138.5m)
Interest Coverage Ratio = 6.13 (Ebit TTM 50.6m / Interest Expense TTM 8.27m)
FCF Yield = -0.31% (FCF TTM -999.0k / Enterprise Value 327.0m)
FCF Margin = -0.28% (FCF TTM -999.0k / Revenue TTM 363.2m)
Net Margin = -3.93% (Net Income TTM -14.3m / Revenue TTM 363.2m)
Gross Margin = 60.97% ((Revenue TTM 363.2m - Cost of Revenue TTM 141.8m) / Revenue TTM)
Gross Margin QoQ = 43.15% (prev 89.57%)
Tobins Q-Ratio = 0.38 (Enterprise Value 327.0m / Total Assets 852.7m)
Interest Expense / Debt = 1.86% (Interest Expense 1.94m / Debt 104.6m)
Taxrate = -13.18% (negative due to tax credits) (6.19m / -47.0m)
NOPAT = 57.3m (EBIT 50.6m * (1 - -13.18%)) [negative tax rate / tax credits]
Current Ratio = 4.31 (Total Current Assets 478.3m / Total Current Liabilities 110.9m)
Debt / Equity = 0.18 (Debt 104.6m / totalStockholderEquity, last fiscal year 567.2m)
Debt / EBITDA = -0.49 (Net Debt -33.3m / EBITDA 67.5m)
Debt / FCF = 33.37 (negative FCF - burning cash) (Net Debt -33.3m / FCF TTM -999.0k)
Total Stockholder Equity = 558.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.67% (Net Income -14.3m / Total Assets 852.7m)
RoE = -2.55% (Net Income TTM -14.3m / Total Stockholder Equity 558.8m)
RoCE = 8.45% (EBIT 50.6m / Capital Employed (Equity 558.8m + L.T.Debt 40.2m))
RoIC = 9.19% (NOPAT 57.3m / Invested Capital 623.8m)
WACC = 9.26% (E(360.9m)/V(465.5m) * Re(11.34%) + D(104.6m)/V(465.5m) * Rd(1.86%) * (1-Tc(-0.13)))
Discount Rate = 11.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 8.43%
Fair Price DCF = unknown (Cash Flow -999.0k)
EPS Correlation: -7.20 | EPS CAGR: -72.04% | SUE: -2.70 | # QB: 0
Revenue Correlation: 86.23 | Revenue CAGR: 17.58% | SUE: 0.40 | # QB: 0

Additional Sources for ACB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle